Alexion Pharmaceuticals (ALXN) Shares are Down -4.6%

Alexion Pharmaceuticals (ALXN) : During the past 4 weeks, traders have been relatively bearish on Alexion Pharmaceuticals (ALXN), hence the stock is down -9.68% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.08% relative to the S&P 500. The 4-week change in the price of the stock is -9.8% and the stock has fallen -4.6% in the past 1 week.

The stock has recorded a 20-day Moving Average of 6.59% and the 50-Day Moving Average is 3.16%.The 200 Day SMA reached 15.85%. Alexion Pharmaceuticals, Inc. has dropped 20.21% during the last 3-month period . Year-to-Date the stock performance stands at -35.17%.


Alexion Pharmaceuticals (NASDAQ:ALXN): The stock opened in the green at $126.29 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $126.29 and a low of $123.56 for the day. The stock did not find buyers even at the lows and closed at $123.67 recording a loss of -1.56%. 1,083,049 shares exchanged hands during the trading day. The stock had closed at $125.63 in the previous days trading.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.